Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

EnVivo Pharmaceuticals Announces Appointment of President and Chief Executive Officer

Published: Friday, July 12, 2013
Last Updated: Friday, July 12, 2013
Bookmark and Share
Industry leader to direct company growth, commercialization of phase 3 programs in Alzheimer’s disease and schizophrenia, and expansion of diverse CNS pipeline.

EnVivo Pharmaceuticals announced the appointment of Deborah Dunsire, M.D., as president and chief executive officer. She also joins the company’s board of directors. Dr. Dunsire, formerly president and chief executive officer of Millennium: The Takeda Oncology Company, brings more than 25 years of scientific, clinical, operational and commercial experience, and proven leadership in the biological and pharmaceutical industry.

Dr. Dunsire served as president and chief executive officer of Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005 to 2013. During that period, she transformed the company into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement and increasing the commercial mindset across the organization to enhance the commercial success of marketed products. The company was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8 billion – one of the largest biotech acquisitions at that time – and became Millennium: The Takeda Oncology Company. Dr. Dunsire was the first woman appointed to Takeda’s board of directors.

“Deborah’s ability to build a fully integrated biopharmaceutical company with an award-winning culture of innovation and successfully commercialize late-stage programs while developing a leading research pipeline is unparalleled,” said Stephen Knight, M.D., chairman of the EnVivo board of directors and president of Fidelity Biosciences. “She joins EnVivo at a transformative point in the company’s evolution, as our lead product, EVP-6124, is in Phase 3 clinical trials in schizophrenia and will enter a Phase 3 clinical trial in Alzheimer’s disease later this year. We are excited to work with Deborah to build EnVivo toward global CNS leadership.

I thank Robert Weisskoff, Ph.D., for his exceptional leadership as interim chief executive officer as he resumes his prior role as a member of the company's board of directors.”

“CNS diseases, including Alzheimer’s disease and schizophrenia, take a devastating toll on patients, families and the health care system,” said Dr. Dunsire. “EnVivo’s late-stage lead product candidate and broad pipeline of promising clinical programs present a unique and compelling opportunity to develop new therapies with the potential to make a dramatic impact on patients’ lives. I am looking forward to working with the EnVivo team to purpose-build a biopharmaceutical company focused on transforming the CNS treatment landscape.”

Prior to leading Millennium, Dr. Dunsire led the Novartis U.S. Oncology Business, playing a critical role in the broad development and successful launch of a number of products. Over 10 years, she increased the North American oncology revenues from $50 million to more than $2.2 billion. She served on the U.S. Pharmaceutical Executive Committee at Novartis. Dr. Dunsire is currently a board member of Allergan, Inc., the Biotechnology Industry Organization (BIO), Museum of Science (Boston), Massachusetts General Hospital Research Advisory Council, CancerCare (New York) and the Gabrielle's Angels Foundation for Cancer Research. She has received numerous awards, including the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare Businesswomen’s Association’s “Woman of the Year”, the 2011 MassBIO Innovator Award and the 2013 Boston CEO Conference Lifetime Achievement award. Dr. Dunsire received her medical degree from the University of Witwatersand, Johannesburg, South Africa.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Substance Can Potentially Postpone Aging
Researchers bridge the gap between two main aging theories - repairs to the DNA and poor functioning mitochondria.
Untangling Cause Of Memory Loss In Neurodegenerative Diseases
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders.
New Model for Understanding Human Myeloma
Researchers develop mouse model where mice carry six human genes involved in human tumour growth.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
New Platform for Roundworms Could Speed Up Drug Delivery
Researchers have developed a large-scale in vitro drug discovery platform that could speed up scientific research.
Scientists Speed Up Muscle Repair
Researchers discovered genetically modified mice were able to support far more regenerative stem cells, for muscle repair, than previously thought.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos